Lutris Pharma is a clinical stage biopharmaceutical company dedicated to enhancing anti-cancer therapies by mitigating cutaneous dose-limiting toxicity. The company is developing LUT014, a topical gel designed to alleviate EGFR inhibitor-induced acneiform rash, thereby potentially improving treatment efficacy and patient quality of life.
Leadership & Board
Current Number of Employees3
Current LinkedIn Followers1,166
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$30M
Total Amount Raised$30M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$30M
Latest Funding Amount$30M
Latest Funding RoundInvestment
Latest Funding RoundInvestment
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
Lutris Pharma had 3 employees as of September 14, 2026. The number of employees increased by 0 (0.00%) week-over-week.
3Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
Lutris Pharma had 1,166 followers as of September 14, 2026. The number of followers increased by 3 (0.26%) week-over-week.
1,166Latest Followers Count
3(0.26%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.